TYK Medicines, Inc. (浙江同源康醫藥股份有限公司) will convene its second Extraordinary General Meeting (EGM) of 2026 at 2:00 p.m. on Friday, 16 October 2026, on the 8th Floor of Building T2, China Eastern Binjiang Center, No. 277 Longlan Road, Xuhui District, Shanghai, PRC.
Key items slated for shareholder vote include:
1. Re-election of seven directors using cumulative voting • Four non-independent directors: – Dr. Wu Yusheng (executive director) – Dr. Li Jun (non-executive) – Dr. Gu Eric Hong (non-executive) – Mr. He Chao (non-executive) • Three independent non-executive directors: – Dr. Leng Yuting – Dr. Xu Wenqing – Dr. Shen Xiuhua
Each H share will carry votes equal to the number of positions available—four votes per share for non-independent director seats and three votes per share for independent non-executive director seats. Shareholders may distribute or concentrate their votes among candidates at their discretion.
2. Special resolution • Proposed amendments to the Articles of Association. Voting options include FOR, AGAINST, or ABSTAIN. Abstentions will be counted as votes with voting rights when calculating results.
Proxy arrangements • Shareholders may appoint the chairman of the meeting or another individual as proxy. • Completed proxy forms, together with any required authorisation documents, must reach Computershare Hong Kong Investor Services Limited (17M Floor, Hopewell Centre, 183 Queen’s Road East, Wan Chai, Hong Kong) no later than 24 hours before the scheduled meeting time. • Attendance in person supersedes a previously submitted proxy.
Identification requirements Shareholders or their proxies must present valid identity documents at the meeting venue. Joint shareholders may have a single representative vote; if multiple joint holders attend, only the vote of the holder named first in the register will be recognised.
No dividend, earnings or financial performance data were included in the announcement; the disclosure is limited to procedural details for the forthcoming EGM and the specific resolutions to be considered.